Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Zi-Yao Huang"'
Autor:
Zi-Jing Li, William Pat Fong, Dong-Sheng Zhang, Hui-Yan Luo, Dong-Liang Chen, Yan-Yu Cai, Zhi-Gang Chen, Jian-Li Duan, Zi-Yao Huang, Yu-Ting Lu, Xiao-Xia Huang, Yu-Hong Li, De-Shen Wang
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-6 (2024)
Abstract Anaplastic lymphoma kinase (ALK) fusion-positive colorectal cancer (CRC) is a rare and chemotherapy-refractory subtype that lacks established and effective treatment strategies. Additionally, the efficacy and safety of ALK inhibitors (ALKi)
Externí odkaz:
https://doaj.org/article/bbdc714779f84f3980277043828d8a35
Autor:
Zi-Yao Huang, Lei Wen, Liu-Fang Ye, Yu-Ting Lu, William Pat Fong, Ren-Jing Zhang, Si-Xian Wu, Zhi-Gang Chen, Yan-Yu Cai, Rui-Hua Xu, Yu-Hong Li, Zi-Ming Du, De-Shen Wang
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: Transmembrane E3 ubiquitin ligase ( RNF43 ) mutations are present in approximately 6–18% of colorectal cancers (CRC) and could enhance Wnt/β-catenin signaling, which is emerging as a promising therapeutic target. This study aims to inv
Externí odkaz:
https://doaj.org/article/d267fbf1f23c40f6a8146f578616f919
Autor:
Liu-Fang Ye, Zi-Yao Huang, Xiao-Xi Chen, Zhi-Gang Chen, Si-Xian Wu, Chao Ren, Ming-Tao Hu, Hua Bao, Ying Jin, Feng Wang, Feng-Hua Wang, Zi-Ming Du, Xue Wu, Huai-Qiang Ju, Yang Shao, Yu-Hong Li, Rui-Hua Xu, De-Shen Wang
Publikováno v:
Drug Resistance Updates. 65:100883
This study aimed to identify mechanisms of drug resistance to the combination of vemurafenib, irinotecan, and cetuximab (VIC) in BRAFForty-one patients with BRAFBRAF mutant in baseline plasma and its dynamics are significantly associated with VIC-rel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aff546b40a554bd5816a44bea5f89ff9
https://doi.org/10.1016/j.drup.2022.100883
https://doi.org/10.1016/j.drup.2022.100883